The Koch Institute announced that Astellas Pharma has joined the BioConvergence Cancer Alliance. As a member of the alliance, Astellas will closely engage with a thriving research community at the Koch Institute and flagship initiatives, as well as explore opportunities for formal scientific collaborations with faculty members at the Institute.
Koch Institute member Rudolf Jaenisch has been recognized for his work that has led to major advances in our understanding of mammalian cloning and embryonic stem cells.
In the White House announcement of his appointment, Koch Institute Director Tyler Jacks was recognized by the President for his depth of experience and tremendous dedication to cancer research.
KI announced a major strategic partnership with Ortho-McNeil-Janssen Pharmaceuticals, Inc., and its affiliates, called TRANSCEND, whereby the parties will begin to collaborate in multiple areas of oncology research and technology development.
MIT has announced a $100 million gift from Koch Industries executive and MIT alumnus David H. Koch that will usher in new paradigms in highly integrative cancer research. The gift will bring together MIT scientists and engineers under one roof to develop new and powerful ways to detect, diagnose, treat, and manage this often deadly disease.
